{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:25:04Z","timestamp":1759411504611,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"zonmw","doi-asserted-by":"publisher","award":["522004008"],"award-info":[{"award-number":["522004008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Maternal immunization confers passive immunity to the fetus by transplacental antibody transfer. Infants may be better protected against pertussis if the mother received a diphtheriae, tetanus and acellular pertussis (Tdap) vaccination in the second trimester of pregnancy compared to the third trimester. This study evaluates IgG antibody concentrations in term and preterm infants at birth and 2 months after birth after maternal Tdap-vaccination between 20<jats:sup>0<\/jats:sup> and 24<jats:sup>0<\/jats:sup> w of gestation vs third trimester Tdap-vaccination. Further aims are assessing the determinants that underlie acceptance of second trimester maternal Tdap-vaccination as well as the tolerability of vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study consists of two parts. In the acceptance part, pregnant women complete a questionnaire on determinants that underlie acceptance of a second trimester Tdap-vaccination, which is offered subsequently between 20<jats:sup>0<\/jats:sup> and 24<jats:sup>0<\/jats:sup> w of gestation. Vaccinated women complete an additional questionnaire on vaccination tolerability. Vaccinated women may also participate in the immunogenicity part, in which blood is drawn from mother at delivery and from infant at birth and 2 months after birth. Women are also eligible for the immunogenicity part if they received a Tdap-vaccination between 20<jats:sup>0<\/jats:sup> and 24<jats:sup>0<\/jats:sup> w of gestation via the national immunization program and get hospitalized for an imminent preterm delivery. Blood sampling continues until 60 term and 60 preterm mother-infant-pairs have been included. Pertussis-specific IgG antibody concentrations are determined in serum using a fluorescent bead-based multiplex immunoassay. For term infants, non-inferiority in IgG antibody concentrations against pertussis toxin (anti-PT) will be assessed referred to a historical control group in which mothers were Tdap-vaccinated between 30<jats:sup>0<\/jats:sup> and 32<jats:sup>0<\/jats:sup> w of gestation. For preterm infants, non-inferiority of anti-PT IgG concentrations is referred to as 85% of infants having\u2009\u2265\u200920 international units\/mL at 2 months after birth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study investigates acceptance, tolerability and immunogenicity regarding maternal Tdap-immunization between 20<jats:sup>0<\/jats:sup> and 24<jats:sup>0<\/jats:sup> w of gestation. Its results provide insight into the effects of second trimester Tdap-vaccination on IgG antibody concentrations in term and preterm infants before primary infant vaccinations. Results on acceptance and tolerability guide antenatal care providers in communication with pregnant women and maintain the safety of second trimester Tdap-vaccination.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: EU Clinical Trials Register, 2018-002976-41, retrospectively registered 24 July 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2018-002976-41\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2018-002976-41<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06559-w","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:14:04Z","timestamp":1630656844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Study protocol of the PIMPI-project, a cohort study on acceptance, tolerability and immunogenicity of second trimester maternal pertussis immunization in relation to term and preterm infants"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-379X","authenticated-orcid":false,"given":"Maarten M.","family":"Immink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille N.","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke Y.","family":"Rots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A. M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoline A. T.","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"49","key":"6559_CR1","first-page":"2657","volume":"142","author":"AL Vegelin","year":"1998","unstructured":"Vegelin AL, van Vught AJ, Wolfs TF, Kimpen JL, Geelen SP. Pertussis in young infants. Ned Tijdschr Geneeskd. 1998;142(49):2657\u201360.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"6559_CR2","unstructured":"Schurink-van't Klooster TM. The National Immunisation Programme in the Netherlands; surveillance and developments in 2015\u20132016. Bilthoven: National Institute for Public Health and the Environment; 2016. Report No.: 2016-0141."},{"issue":"5","key":"6559_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1473-3099(16)00027-X","volume":"16","author":"M van Wijhe","year":"2016","unstructured":"van Wijhe M, McDonald SA, de Melker HE, Postma MJ, Wallinga J. Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. Lancet Infect Dis. 2016;16(5):592\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"6559_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3201\/eid0604.000404","volume":"6","author":"HE de Melker","year":"2000","unstructured":"de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MAE. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6(4):348\u201357.","journal-title":"Emerg Infect Dis"},{"issue":"41","key":"6559_CR5","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1016\/j.vaccine.2013.07.060","volume":"31","author":"NAT van der Maas","year":"2013","unstructured":"van der Maas NAT, Mooi FR, de Greeff SC, Berbers GAM, Conyn-Spaendonck MAE, de Melker HE. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine. 2013;31(41):4541\u20137.","journal-title":"Vaccine"},{"issue":"10","key":"6559_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1086\/652281","volume":"50","author":"SC de Greeff","year":"2010","unstructured":"de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339\u201345.","journal-title":"Clin Infect Dis"},{"key":"6559_CR7","doi-asserted-by":"crossref","unstructured":"whooping cough vaccination; coverage may be widened. Br Med J (Clin Res Ed). 2012;345(7868):E5201.","DOI":"10.1136\/bmj.e5201"},{"issue":"5","key":"6559_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","volume":"36","author":"A Malek","year":"1996","unstructured":"Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248\u201355.","journal-title":"Am J Reprod Immunol"},{"issue":"suppl_4","key":"6559_CR9","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1093\/cid\/ciw559","volume":"63","author":"G Amirthalingam","year":"2016","unstructured":"Amirthalingam G, Campbell H, Ribeiro S, Fry AM, Ramsay M, Miller CA, et al. sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. CID. 2016;63(suppl_4):S236-43.","journal-title":"CID"},{"key":"6559_CR10","doi-asserted-by":"publisher","first-page":"g4219","DOI":"10.1136\/bmj.g4219","volume":"349","author":"K Donegan","year":"2014","unstructured":"Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ. 2014;349:g4219.","journal-title":"BMJ"},{"key":"6559_CR11","volume-title":"Vaccinatie tegen kinkhoest: doel en strategie","author":"Gezondheidsraad","year":"2015","unstructured":"Gezondheidsraad. Vaccinatie tegen kinkhoest: doel en strategie. Den Haag: Gezondheidsraad; 2015."},{"issue":"3","key":"6559_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/archdischild-2016-311802","volume":"103","author":"L Byrne","year":"2017","unstructured":"Byrne L, Campbell H, Andrews N, Ribeiro S, Amirthalingam G. Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. Arch Dis Child. 2017;103(3):224\u20139.","journal-title":"Arch Dis Child"},{"issue":"5","key":"6559_CR13","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1097\/INF.0000000000001545","volume":"36","author":"OR Riise","year":"2017","unstructured":"Riise OR, Laake I, Vestrheim D, Flem E, Moster D, Riise Bergsaker MA, et al. Risk of pertussis in relation to degree of prematurity in children less than 2 years of age. Pediatr Infect Dis J. 2017;36(5):e151\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"6559_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1186\/s12879-019-4563-5","volume":"19","author":"NAT van der Maas","year":"2019","unstructured":"van der Maas NAT, Sanders EAM, Versteegh FGA, Baauw A, Westerhof A, de Melker HE. Pertussis hospitalizations among term and preterm infants: clinical course and vaccine effectiveness. BMC Infect Dis. 2019;19(1):919.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"6559_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jinf.2016.11.003","volume":"74","author":"G Amirthalingam","year":"2017","unstructured":"Amirthalingam G, Brown CS, Campbell H, Chand MA, Fry NK. New Public Health England guidelines for managing pertussis in England. J Infect. 2017;74(2):202\u20134.","journal-title":"J Infect"},{"key":"6559_CR16","unstructured":"Pertussis vaccination programme for pregnant women update: vaccine coverage in England, April to June 2018. Public Health England; 2018."},{"key":"6559_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa836","author":"E Tessier","year":"2020","unstructured":"Tessier E, Campbell H, Ribeiro S, Fry NK, Brown C, Stowe J, et al. Impact of extending the timing of maternal pertussis vaccination on hospitalized infant pertussis in England, 2014\u20132018. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa836.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"6559_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/cid\/ciw027","volume":"62","author":"CS Eberhardt","year":"2016","unstructured":"Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis. 2016;62(7):829\u201336.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6559_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/cid\/cix046","volume":"64","author":"CS Eberhardt","year":"2017","unstructured":"Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Combescure C, Othenin-Girard V, Chilin A, et al. Pertussis antibody transfer to preterm neonates after second-versus third-trimester maternal immunization. Clin Infect Dis. 2017;64(8):1129\u201332.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6559_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/cid\/ciw634","volume":"64","author":"K Winter","year":"2017","unstructured":"Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017;64(1):3\u20138.","journal-title":"Clin Infect Dis"},{"issue":"18","key":"6559_CR21","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1016\/j.vaccine.2012.02.030","volume":"30","author":"A van Lier","year":"2012","unstructured":"van Lier A, Steens A, Ferreira JA, van der Maas NA, de Melker HE. Acceptance of vaccination during pregnancy: experience with 2009 influenza A (H1N1) in the Netherlands. Vaccine. 2012;30(18):2892\u20139.","journal-title":"Vaccine"},{"issue":"41","key":"6559_CR22","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1016\/j.vaccine.2015.08.028","volume":"33","author":"CM Healy","year":"2015","unstructured":"Healy CM, Rench MA, Montesinos DP, Ng N, Swaim LS. Knowledge and attitiudes of pregnant women and their providers towards recommendations for immunization during pregnancy. Vaccine. 2015;33(41):5445\u201351.","journal-title":"Vaccine"},{"issue":"1\u20132","key":"6559_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jim.2008.02.018","volume":"335","author":"PG van Gageldonk","year":"2008","unstructured":"van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335(1\u20132):79\u201389.","journal-title":"J Immunol Methods"},{"issue":"4","key":"6559_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1473-3099(18)30717-5","volume":"19","author":"D Barug","year":"2019","unstructured":"Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, et al. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis. 2019;19(4):392\u2013401.","journal-title":"Lancet Infect Dis"},{"issue":"40","key":"6559_CR25","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1016\/j.vaccine.2020.07.047","volume":"38","author":"C Anraad","year":"2020","unstructured":"Anraad C, Lehmann BA, Visser O, van Empelen P, Paulussen TGW, Ruiter RAC, et al. Social-psychological determinants of maternal pertussis vaccination acceptance during pregnancy among women in the Netherlands. Vaccine. 2020;38(40):6254\u201366.","journal-title":"Vaccine"},{"key":"6559_CR26","unstructured":"Peristat: Perined; 2019. Available from: https:\/\/www.peristat.nl\/."},{"issue":"11","key":"6559_CR27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/cid\/civ695","volume":"61","author":"SN Ladhani","year":"2015","unstructured":"Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin Infect Dis. 2015;61(11):1637\u201344.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"6559_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1097\/INF.0b013e3182a09b6a","volume":"32","author":"AJ Hardy-Fairbanks","year":"2013","unstructured":"Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, Greenberg DP, Kirkland KB, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013;32(11):1257\u201360.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"6559_CR29","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S1473-3099(17)30190-1","volume":"17","author":"B Abu Raya","year":"2017","unstructured":"Abu Raya B, Edwards KM, Scheifele DW, Halperin SA. Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis. 2017;17(7):e209\u201322.","journal-title":"Lancet Infect Dis"},{"key":"6559_CR30","unstructured":"General grant conditions: ZonMW. Available from: https:\/\/www.zonmw.nl\/en\/news-and-funding\/funding\/grant-conditions-and-finances\/."},{"key":"6559_CR31","unstructured":"Schurink-van't Klooster TM, de Melker HE. The National Immunisation Programme in the Netherlands\u2014Surveillance en Developments in 2019\u20132020. 2020."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06559-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:17:09Z","timestamp":1630657029000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06559-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6559"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06559-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Central Committee on Research Involving Human Subjects in the Netherlands (Registration Number: NL66966.000.18). All participants provide written informed consent for participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"897"}}